175
Participants
Start Date
May 3, 2023
Primary Completion Date
February 29, 2024
Study Completion Date
April 25, 2024
AND017 capsules TIW
Orally, 3 times per week in Period 1 and dose adjustment in Period 2 at 2 mg/4 mg and 2-weeks interval according to Hb levels
AND017 capsules QW
Orally, once per week in Period 1 and dose adjustment in Period 2 at 4 mg/8 mg and 2-weeks interval according to Hb levels
epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars
Dose regimen and adjustment rules according to the USPI or SmPC or local practice
Nephrology Associates of Western New York, Cheektowaga
Nephrology and Hypertension Specialists, Dalton
Nephrology Consultants of Northwest Ohio - Toledo, Toledo
US Renal Care - Pine Bluff, Pine Bluff
South Texas Renal Care Group - San Saba, San Antonio
Clinical Advancement Center PLLC, San Antonio
South Texas Renal Care Group, San Antonio
Rocky Mountain Kidney Care, Lone Tree
High Desert Nephrology Associates, Gallup
North America Research Institute, Riverside
The Affiliated Zhongshan Hospital of Dalian University, Dalian
Zhongshan Hospital affiliated to Fudan University, Shanghai
Jinshan Hospital Affiliated to Fudan University, Shanghai
Second Affiliated Hospital of Nanjing Medical University, Nanjing
The First People's Hospital of Changzhou, Changzhou
Second Affiliated Hospital of Soochow University, Suzhou
The First Affiliated Hospital of Xiamen University, Xiamen
Xiamen Branch, Zhongshan hospital affilicated to Fudan University, Xiamen
Xiamen Fifth Hospital, Xiamen
The Second Affiliated Hospital of Chongqing Medical University, Chongqing
Renmin Hospital of Wuhan University, Wuhan
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang
Sichuan Provincial People's Hospital, Chengdu
Zigong First People's Hospital, Zigong
First Affiliated Hospital of Xi'an Jiaotong University, Xi’an
Lead Sponsor
Kind Pharmaceuticals LLC
INDUSTRY